The potential role in HIFU telehealth in the management of fibroid and adenomyosis after COVID-19 pandemic

Wu Shun Felix Wong 1, *, Yonghua Xu 2 and Lian Zhang 3

1 School of Women’s and Children’s Health, The University of New South Wales, NSW, Australia.

2 Department of Imaging and Interventional Radiology at Shanghai Xuhui District Central Hospital, Shanghai, China.

3 State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, China.

Review Article
World Journal of Advanced Research and Reviews, 2021, 09(02), 027-031
Article DOI: 10.30574/wjarr.2021.9.2.0032
 
Publication history: 
Received on 15 January  2021; revised on 23 January  2021; accepted on 25 January  2021
 
Abstract: 
We come to realize the importance of “telehealth” during the current COVID-19 pandemic. Telehealth can be defined as providing health care, including preventive, diagnostic, and treatment services, by using information and communication technologies such as videoconferencing, electronic messaging, and telephone calls (1). With the rapid development of new treatment technology, communication, and fast speed networks, not only telehealth can provide medical services closer to home, but it also should provide the doctors and patients with additional benefits of safety, effectiveness, and satisfaction. HIFU is a new non-invasive ablation treatment for many solid tumors. This paper illustrates how the potential practice of HIFU ablation for fibroids can be modified to make it suitable for doctors in their HIFU training for treatment of fibroids and adenomyosis and for patients who need surgery using this new telehealth development.
 
Keywords: 
HIFU ablation; Telehealth; Fibroid; Adenomyosis; 5G
 
Full text article in PDF: 
Share this